First Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Athens University Medical School, National and Kapodistrian University of Athens, Greece.
Metabolism. 2020 May;106:154172. doi: 10.1016/j.metabol.2020.154172. Epub 2020 Feb 4.
Preeclampsia represents a major pregnancy complication, associated with high rates of perinatal morbidity. The aim of this systematic review is to accumulate current literature evidence in order to examine the pattern of serum adipokine levels among preeclamptic women and asses their potential efficacy in the prediction of the disease.
Medline, Scopus, CENTRAL, Clinicaltrials.gov and Google Scholar databases were systematically searched from inception. All observational studies reporting serum adipokine values among preeclamptic and healthy pregnant women were held eligible.
A total of 163 studies were included, comprising 23,482 women. Leptin was evaluated in 91 studies and its values were found to be significantly elevated in preeclamptic women during all pregnancy trimester, independently of disease onset and severity. Preeclampsia was also associated with increased serum fatty acid binding protein-4 and chemerin levels, when measured both during the 1st and 3rd trimester. Data concerning the rest adipokines were either conflicting or limited to reach firm conclusions. Quality of evidence was evaluated to be high for leptin, moderate for serum fatty acid binding protein-4 and chemerin and low for the other adipokines.
The existing evidence suggests that preeclampsia is linked to increased levels of leptin, chemerin and fatty acid binding protein-4 in all pregnancy trimesters and forms of the disease. Inconsistent data currently exists concerning the role of the other adipokines. Large-scale prospective studies should longitudinally evaluate the serum concentration of novel adipokines and define the optimal threshold and timing of measurement to be widely applied in clinical practice.
子痫前期是一种主要的妊娠并发症,与围产期发病率高有关。本系统评价的目的是积累当前的文献证据,以检查子痫前期妇女血清脂联素水平的模式,并评估其在疾病预测中的潜在效果。
系统地检索了 Medline、Scopus、CENTRAL、Clinicaltrials.gov 和 Google Scholar 数据库,从开始到现在。所有报告子痫前期和健康孕妇血清脂联素值的观察性研究都符合条件。
共纳入 163 项研究,包括 23482 名女性。评估了 91 项研究中的瘦素,发现其值在所有妊娠三期中均显著升高,与疾病的发生和严重程度无关。子痫前期还与血清脂肪酸结合蛋白-4 和趋化素水平升高有关,这些水平在第 1 期和第 3 期均可测量。关于其他脂联素的数据要么相互矛盾,要么限于得出确切结论。瘦素的证据质量评估为高,血清脂肪酸结合蛋白-4 和趋化素的证据质量评估为中,而其他脂联素的证据质量评估为低。
现有证据表明,子痫前期与所有妊娠三期中瘦素、趋化素和脂肪酸结合蛋白-4水平升高有关,且疾病的各种形式均有关联。关于其他脂联素的作用,目前存在不一致的数据。应进行大规模前瞻性研究,以纵向评估新型脂联素的血清浓度,并确定最佳阈值和测量时间,以便在临床实践中广泛应用。